Arbutus Biopharma (ABUS) Competitors $3.40 -0.07 (-2.02%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.33 -0.07 (-1.94%) As of 08/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS vs. GMTX, XENE, OGN, AMRX, NAMS, KNSA, RXRX, ARWR, BLTE, and IDYAShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Gemini Therapeutics (GMTX), Xenon Pharmaceuticals (XENE), Organon & Co. (OGN), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Its Competitors Gemini Therapeutics Xenon Pharmaceuticals Organon & Co. Amneal Pharmaceuticals NewAmsterdam Pharma Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Arrowhead Pharmaceuticals Belite Bio IDEAYA Biosciences Arbutus Biopharma (NASDAQ:ABUS) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment. Do analysts recommend ABUS or GMTX? Arbutus Biopharma presently has a consensus target price of $5.50, suggesting a potential upside of 61.76%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Arbutus Biopharma is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ABUS or GMTX? Arbutus Biopharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Does the media favor ABUS or GMTX? In the previous week, Arbutus Biopharma had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Arbutus Biopharma and 1 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 1.00 beat Gemini Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ABUS or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -352.24%. Gemini Therapeutics' return on equity of -38.78% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-352.24% -57.48% -41.86% Gemini Therapeutics N/A -38.78%-35.88% Which has preferable earnings & valuation, ABUS or GMTX? Arbutus Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.17M105.54-$69.92M-$0.41-8.29Gemini TherapeuticsN/AN/A-$71.87M-$1.00-59.00 Do institutionals & insiders hold more shares of ABUS or GMTX? 43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryArbutus Biopharma beats Gemini Therapeutics on 11 of the 15 factors compared between the two stocks. Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$664.60M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.18%P/E Ratio-11.7217.9729.8725.14Price / Sales105.54262.19422.9397.17Price / CashN/A41.8335.9458.58Price / Book6.677.238.105.59Net Income-$69.92M-$54.43M$3.26B$265.48M7 Day Performance3.98%0.22%0.64%1.22%1 Month Performance6.92%5.59%2.42%0.39%1 Year Performance-5.56%9.98%27.60%23.47% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma2.7802 of 5 stars$3.40-2.0%$5.50+61.8%-3.1%$664.60M$6.17M-11.7290News CoveragePositive NewsEarnings ReportGMTXGemini TherapeuticsN/A$58.97-1.3%N/A+40.1%$2.56BN/A-58.9730XENEXenon Pharmaceuticals3.0891 of 5 stars$33.16+8.7%$54.82+65.3%-16.7%$2.54B$9.43M-10.27210Upcoming EarningsOptions VolumeHigh Trading VolumeOGNOrganon & Co.4.8341 of 5 stars$9.68-0.7%$18.00+86.0%-52.2%$2.52B$6.29B3.364,000Trending NewsEarnings ReportDividend AnnouncementAMRXAmneal Pharmaceuticals3.6293 of 5 stars$7.96+1.7%$11.60+45.7%+20.6%$2.49B$2.79B-198.958,100Earnings ReportNAMSNewAmsterdam Pharma3.4752 of 5 stars$21.66+1.8%$41.30+90.7%+46.6%$2.43B$45.56M-11.524News CoverageEarnings ReportAnalyst ForecastKNSAKiniksa Pharmaceuticals International2.7054 of 5 stars$32.95+3.0%$41.17+24.9%+37.9%$2.40B$529.33M823.96220Insider TradeRXRXRecursion Pharmaceuticals1.877 of 5 stars$5.80+2.1%$7.00+20.7%-15.1%$2.36B$59.82M-3.28400Earnings ReportARWRArrowhead Pharmaceuticals3.8287 of 5 stars$16.47+3.4%$43.71+165.4%-35.8%$2.27B$3.55M-11.76400Earnings ReportAnalyst RevisionBLTEBelite Bio2.2206 of 5 stars$69.79+6.2%$96.67+38.5%+49.9%$2.22BN/A-51.3210Upcoming EarningsIDYAIDEAYA Biosciences4.1949 of 5 stars$25.00+3.0%$48.09+92.4%-37.5%$2.19B$7M-6.9680Earnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies GMTX Alternatives XENE Alternatives OGN Alternatives AMRX Alternatives NAMS Alternatives KNSA Alternatives RXRX Alternatives ARWR Alternatives BLTE Alternatives IDYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABUS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts